日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting mitochondrial bioenergetics: the "Achilles' heel" of Leishmania.

靶向线粒体生物能量学:利什曼原虫的“阿喀琉斯之踵”。

Sarkar Deblina, De Sarkar Sritama, Goswami Deep, Chatterjee Mitali

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2

靶向帕金森病相关LRRK2的II型激酶抑制剂

Nicolai D Raig ,Katherine J Surridge ,Marta Sanz-Murillo ,Verena Dederer ,Andreas Krämer ,Martin P Schwalm ,Nicholas M Lattal ,Lewis Elson ,Deep Chatterjee ,Sebastian Mathea ,Thomas Hanke ,Andres E Leschziner ,Samara L Reck-Peterson ,Stefan Knapp

Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2

针对帕金森病相关 LRRK2 的 II 型激酶抑制剂

Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, Verena Dederer, Andreas Krämer, Martin P Schwalm, Lewis Elson, Deep Chatterjee, Sebastian Mathea, Thomas Hanke, Andres E Leschziner, Samara L Reck-Peterson, Stefan Knapp

A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2

一种设计的锚蛋白重复蛋白,靶向帕金森病相关的 LRRK2

Verena Dederer, Marta Sanz Murillo, Eva P Karasmanis, Kathryn S Hatch, Deep Chatterjee, Franziska Preuss, Kamal R Abdul Azeez, Landon Vu Nguyen, Christian Galicia, Birgit Dreier, Andreas Plückthun, Wim Versees, Sebastian Mathea, Andres E Leschziner, Samara L Reck-Peterson, Stefan Knapp

Structure of LRRK1 and mechanisms of autoinhibition and activation

LRRK1 的结构以及自身抑制和激活机制

Janice M Reimer, Andrea M Dickey #, Yu Xuan Lin #, Robert G Abrisch #, Sebastian Mathea, Deep Chatterjee, Elizabeth J Fay, Stefan Knapp, Matthew D Daugherty, Samara L Reck-Peterson, Andres E Leschziner

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures

型和 II 型激酶抑制剂对帕金森病相关 LRRK2 的抑制:活性和结构

Marta Sanz Murillo, Amalia Villagran Suarez, Verena Dederer, Deep Chatterjee, Jaime Alegrio Louro, Stefan Knapp, Sebastian Mathea, Andres E Leschziner

Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA

吡咯烷二酮作为细菌酶 MurA 新型抑制剂的鉴定和生化特性

Reem K Fathalla, Wolfgang Fröhner, Chantal D Bader, Patrick D Fischer, Charlotte Dahlem, Deep Chatterjee, Sebastian Mathea, Alexandra K Kiemer, Haribabu Arthanari, Rolf Müller, Mohammad Abdel-Halim, Christian Ducho, Matthias Engel

PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain

PKC 同工型通过磷酸化 CORB GTPase 结构域内的保守残基 (Ser1064、Ser1074 和 Thr1075) 来激活 LRRK1 激酶

Asad U Malik #, Athanasios Karapetsas #, Raja S Nirujogi, Deep Chatterjee, Toan K Phung, Melanie Wightman, Robert Gourlay, Nick Morrice, Sebastian Mathea, Stefan Knapp, Dario R Alessi

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

纳米抗体作为帕金森病相关 LRRK2 的变构调节剂

Ranjan K Singh, Ahmed Soliman, Giambattista Guaitoli, Eliza Störmer, Felix von Zweydorf, Thomas Dal Maso, Asmaa Oun, Laura Van Rillaer, Sven H Schmidt, Deep Chatterjee, Joshua A David, Els Pardon, Thomas U Schwartz, Stefan Knapp, Eileen J Kennedy, Jan Steyaert, Friedrich W Herberg, Arjan Kortholt, C

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors

使用选择性 CDK9 抑制剂调节前列腺癌中的雄激素受体驱动的转录

André Richters, Shelby K Doyle, David B Freeman, Christina Lee, Becky S Leifer, Sajjeev Jagannathan, Florian Kabinger, Jošt Vrabič Koren, Nicholas B Struntz, Julie Urgiles, Ryan A Stagg, Brice H Curtin, Deep Chatterjee, Sebastian Mathea, Peter J Mikochik, Tamara D Hopkins, Hua Gao, Jonathan R Branch